LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

LLY

762.24

-0.35%↓

JNJ

177.06

+0.28%↑

ABBV

219.97

+1.65%↑

UNH

340.04

-0.16%↓

AZN

77.55

-0.35%↓

Search

REVOLUTION Medicines Inc

Deschisă

SectorSănătate

44.74 -1.67

Rezumat

Modificarea prețului

24h

Curent

Minim

44.24

Maxim

45.56

Indicatori cheie

By Trading Economics

Venit

-34M

-248M

EPS

-1.13

Marjă de profit

-74.379

Angajați

700

EBITDA

-24M

-261M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+54.2% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

750M

7.7B

Deschiderea anterioară

46.41

Închiderea anterioară

44.74

Sentimentul știrilor

By Acuity

33%

67%

113 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 sept. 2025, 17:03 UTC

Principalele dinamici ale pieței

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept. 2025, 16:49 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

GD Culture Shares Drop After Deal for Pallas Capital

16 sept. 2025, 16:11 UTC

Principalele dinamici ale pieței

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept. 2025, 21:10 UTC

Achiziții, Fuziuni, Preluări

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 sept. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

16 sept. 2025, 20:25 UTC

Câștiguri

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept. 2025, 20:24 UTC

Câștiguri

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept. 2025, 18:40 UTC

Achiziții, Fuziuni, Preluări

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept. 2025, 16:53 UTC

Câștiguri

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

16 sept. 2025, 16:15 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Commodities Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Energy Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparație

Modificare preț

REVOLUTION Medicines Inc Așteptări

Obiectiv de preț

By TipRanks

54.2% sus

Prognoză pe 12 luni

Medie 71.24 USD  54.2%

Maxim 80 USD

Minim 37.91 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruREVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

15

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

40.67 / 41.96Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

113 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat